Adverse Effect of Prolonged Methylphenidate Treatment on Cardiac Functions
1 other identifier
observational
50
1 country
1
Brief Summary
The purpose of this study is to find out whether prolonged treatment with methylphenidate has any adverse effect on cardiac functions and measurements.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Aug 2006
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2006
CompletedFirst Submitted
Initial submission to the registry
September 3, 2006
CompletedFirst Posted
Study publicly available on registry
September 6, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2012
CompletedSeptember 20, 2012
September 1, 2012
September 3, 2006
September 19, 2012
Conditions
Keywords
Eligibility Criteria
Children aged 8-18 that are at least 5 years on methylphenidates
You may qualify if:
- Children with ADHD aged 8-18 years who are taking methylphenydate (Ritalin©, Ritalin SR©, Ritalin LA©) for more than 5 years.
You may not qualify if:
- Children with any known heart disease or anomaly. Children whose ADHD is part of a syndrome or are mentally retarded. Children that are on any other chronic medications.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ornit Cohenlead
Study Sites (1)
Pediatric Day Care Center, The Barzilai Medical Center
Ashkelon, 78306, Israel
Related Publications (4)
Cohen AL, Jhung MA, Budnitz DS. Stimulant medications and attention deficit-hyperactivity disorder. N Engl J Med. 2006 May 25;354(21):2294-5. doi: 10.1056/NEJMc060860. No abstract available.
PMID: 16723627BACKGROUNDWooltorton E. Medications for attention deficit hyperactivity disorder: cardiovascular concerns. CMAJ. 2006 Jul 4;175(1):29. doi: 10.1503/cmaj.060718. Epub 2006 Jun 13. No abstract available.
PMID: 16772535BACKGROUNDNissen SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006 Apr 6;354(14):1445-8. doi: 10.1056/NEJMp068049. Epub 2006 Mar 20. No abstract available.
PMID: 16549404BACKGROUNDDebate over warnings for ADHD stimulants. Child Health Alert. 2006 Apr;24:1. No abstract available.
PMID: 16673500BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Shraga Aviner, MD, PhD
The Barzilai Medical Center, Ashkelon, Israel
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- r&d unit
Study Record Dates
First Submitted
September 3, 2006
First Posted
September 6, 2006
Study Start
August 1, 2006
Study Completion
December 1, 2012
Last Updated
September 20, 2012
Record last verified: 2012-09